MoonLake Immunotherapeutics
$ 18.34
3.09%
17 Apr - close price
- Market Cap 1,315,489,000 USD
- Current Price $ 18.34
- High / Low $ 18.57 / 18.13
- Stock P/E N/A
- Book Value 4.27
- EPS -3.53
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -0.61 %
- 52 Week High 62.75
- 52 Week Low 5.95
About
MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to developing groundbreaking therapies for chronic inflammatory diseases, leveraging its proprietary drug delivery technology. Currently, the company is advancing its lead candidate, a novel interleukin-17 inhibitor, through various stages of clinical trials, with the potential to transform treatment paradigms and improve patient outcomes significantly. Backed by a robust research pipeline and strategic collaborations, MoonLake is strategically positioned within the immunotherapy sector, targeting significant unmet medical needs while creating potential value for investors.
Analyst Target Price
$26.71
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-05 | 2025-08-05 | 2025-05-05 | 2025-02-26 | 2024-11-12 | 2024-08-07 | 2024-05-07 | 2024-02-29 | 2023-11-14 | 2023-08-10 | 2023-05-12 |
| Reported EPS | -0.92 | -1.1 | -0.87 | -0.63 | -0.72 | -0.56 | -0.39 | -0.22 | -0.12 | -0.18 | -0.23 | -0.23 |
| Estimated EPS | -0.9792 | -0.8788 | -0.72 | -0.7355 | -0.5928 | -0.44 | -0.28 | -0.19 | -0.23 | -0.23 | -0.27 | -0.31 |
| Surprise | 0.0592 | -0.2212 | -0.15 | 0.1055 | -0.1272 | -0.12 | -0.11 | -0.03 | 0.11 | 0.05 | 0.04 | 0.08 |
| Surprise Percentage | 6.0458% | -25.1707% | -20.8333% | 14.344% | -21.4575% | -27.2727% | -39.2857% | -15.7895% | 47.8261% | 21.7391% | 14.8148% | 25.8065% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.91 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MLTX
2026-04-17 07:40:00
Insiders at MoonLake Immunotherapeutics (MLTX) have recently sold shares, with Co-Founder Jorge da Silva netting US$2.8m and Co-Founder & Chief Scientific Officer Kristian Reich selling US$3.0m worth. While there's significant insider ownership (10% or US$140m), the sales, particularly below the current share price, might suggest insiders view the stock as fully valued, despite it not necessarily being a strong negative indicator. The article recommends careful consideration of these transactions alongside other risk factors for the company.
2026-04-16 20:10:19
MoonLake Immunotherapeutics CFO Matthias Bodenstedt sold 2,426 Class A ordinary shares on April 14, 2026, at a weighted average price of $19.56 per share. This transaction was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025. Following the sale, Bodenstedt directly holds 1,186,084 Class A ordinary shares.
2026-04-15 06:40:40
MoonLake Immunotherapeutics CEO Jorge Santos da Silva sold 150,000 Class A ordinary shares in open-market transactions on April 10 and April 13, 2026, for a total value of approximately $2.75 million. These sales were conducted under Rule 144 of the Securities Act, indicating resales of already-owned shares. Despite the sale, Santos da Silva retains a substantial holding of 2,924,893 Class A ordinary shares, signaling a reduction in his equity position but not an exit.
2026-04-11 17:38:49
MoonLake Immunotherapeutics' CFO, Matthias Bodenstedt, sold a total of 87,795 Class A ordinary shares in open-market transactions on April 9 and 10, 2026. These sales, conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025, were intended to cover tax liabilities. Following these transactions, Bodenstedt directly holds 1,188,510 Class A ordinary shares.
2026-04-10 13:39:43
MoonLake Immunotherapeutics (NASDAQ: MLTX) has filed a Form 144, indicating an intent to sell Class A common shares. The filing specifies 150,000 shares for proposed sale, with 3,027,483 shares obtained via exchange on October 1, 2023, and lists UBS Financial Services Inc. as the broker. This regulatory disclosure signals a potential resale of restricted shares but does not confirm an executed sale, price, or timing.
2026-04-09 07:10:26
Insmed Incorporated announced that its Phase 2b CEDAR study for brensocatib in hidradenitis suppurativa failed to meet primary and secondary efficacy endpoints, leading to the discontinuation of the program. Despite the drug showing no efficacy, it was well-tolerated with no new safety signals. Analysts noted the predictable outcome due to challenges in HS clinical trials and prior study failures, but expect continued upside for Insmed shares from its Brinsupri launch.
